Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Romosozumab - Amgen/UCB

Next Previous
Drug Profile

Romosozumab - Amgen/UCB

Alternative Names: AMG-785; Anti-sclerostin; Anti-sclerostin monoclonal antibody; CDP-7851; EVENITY; romosozumab-aqqg; Sclerostin Ab

Latest Information Update: 17 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ChiroscienceGroup plc
  • Developer Amgen; UCB
  • Class Monoclonal antibodies; Osteoporosis therapies
  • Mechanism of Action SOST protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Male osteoporosis; Postmenopausal osteoporosis
  • Phase III Osteogenesis imperfecta; Osteoporosis
  • Discontinued Fracture

Most Recent Events

  • 17 Mar 2026 Amgen plans to initiate a phase III trial for Osteogenesis Imperfecta (Treatment-experienced, In children, Adolescents) in Australia, Austria, Belgium, Canada, China, Germany, Hungary, Japan, Slovakia, Switzerland, Turkey, United Kingdom (SC) (CTIS2023-503293-21-00)
  • 17 Nov 2025 Amgen completes a phase-III trial in Osteoporosis in USA (NCT04779216)
  • 05 Sep 2025 Efficacy data from a phase I trial in Osteogenesis imperfecta presented at the Annual Meeting of the American Society for Bone and Mineral Research 2025 (ASBMR-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top